cyrilzakka/clinical-trials huggingface dataset:
NOWOX Oxygen Therapy Monitoring Device

The purpose of this study is to evaluate the duration of oxygen use recorded by the NOWOX, under usual conditions of daily living, in patients with chronic obstructive respiratory disease requiring oxygen therapy.

Long Term Oxygen Therapy (LTOT) is one of the main non pharmacologic treatments for patients with severe lung disease. This continuous or sub-continuous oxygen supplementation is generally introduced at home in patients who have chronic cardio respiratory failure and severe resting hypoxemia to maintain sufficient blood oxygenation and therefore preserve vital organ function.

LTOT effectiveness has mainly been evaluated and documented in patients with COPD, which also accounts for most of its prescriptions. In these patients, LTOT has been shown to have a beneficial impact on haemodynamics, exercise capacity, lung mechanics and mental state. Its implementation was furthermore associated with reduced yearly hospitalisation days and increased survival Measuring adherence is an extremely important and under-evaluated component of oxygen therapy. NOWOX, medical device has been designed,developed and manufactured to measure adherence to LTOT and additionally to measure patient's respiration rate

Eligibility Criteria:
Inclusion Criteria:

* Male or female patient aged ≥ 18 years and ≤ 75 years,
* Having a documented diagnosis of moderately severe to severe chronic obstructive respiratory disease
* Hospitalised or out-patient requiring transient or long term oxygen therapy,
* Able to be weaned from oxygen for several consecutive minutes (around 30 minutes, SpO2 at rest on room air should not drop \< 85%),
* Able to read
* Willing and able to complete the requirements of this study including providing his/her signature for the written informed consent.

Exclusion Criteria:

* Clinically unstable patient,
* Any contraindication to perform a light cycling exercise, according to the 2003 ATS/ACCP guidelines
* Tracheostomy,
* Nasal obstruction or acute rhinitis occurring in the week prior to selection,
* For female patient:
* Pregnant,
* Positive urinary pregnancy test
* Lactating mother or lack of efficient contraception
* Clinically significant or uncontrolled cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, autoimmune, neurological or psychiatric disorders which may interfere with the study procedures,
* Known allergic reactions to medical material compounds used in the study
* Drug abuse or psychic disorders
* Legal status which prohibits informed consent,
* Participation in any interventional clinical trial within 30 days prior to selection.
Early Recovery After Surgery (ERAS) Versus Conventional Protocol After Laparoscopic Gastrectomy

Enhanced Recovery After Surgery (ERAS) programs have been introduced with purposes of reducing the surgical stress response and obtaining optimal recovery after surgery.

There is strong evidence of the usefulness of the ERAS programs in patients undergoing colorectal surgery in terms of significantly reduced postoperative complications and shorter length of hospital stay, compared to the patients of conventional treatment.

However, few studies exist about the implication of ERAS programs in the laparoscopic gastrectomy.

The aim of this study was to compare the recovery rate, morbidity, and quality of life in the patients undergoing laparoscopic gastrectomy for gastric cancer, receiving either ERAS protocol or conventional postoperative cares.

Eligibility Criteria:
Inclusion Criteria:

* Elective surgery
* American Society of Anesthesiologists (ASA) scores \< 3
* 20 \< Age \< 80
* Gastric cancer, adenocarcinoma, possible to perform laparoscopic distal gastrectomy
* Informed consent
* No other treatment (Radiation, Chemotherapy or Immunotherapy) on this gastric cancer or other type of cancer.
* No systemic inflammatory disease

Exclusion Criteria:

* Emergency operation
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation.


Eligibility Criteria:
Inclusion Criteria:

1. Subjects with a histopathological diagnosis of HCC.
2. Subjects who have undergone a curative resection or ablation (radiofrequency ablation \[RFA\] or microwave ablation \[MVA\] only).
3. No previous systematic treatment and locoregional therapy for HCC prior to randomization.
4. Absence of major macrovascular invasion.
5. No extrahepatic spread.
6. Full recovery from Curative resection or ablation within 4 weeks prior to randomization.
7. High risk for HCC recurrence after resection or ablation.
8. For patients who received post-operative transarterial chemoembolization: full recovery from the procedure within 4 weeks prior to randomization.
9. Child-Pugh Class: Grade A.
10. ECOG-PS score: 0 or 1.
11. Subjects with HCV- RNA (+) must receive antiviral therapy.
12. Adequate organ function.

Exclusion Criteria:

1. Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and fibrolamellar HCC; other active malignant tumor except HCC within 5 years or simultaneously.
2. Evidence of residual lesion, recurrence, and metastasis at randomization.
3. Moderate-to-severe ascites with clinical symptoms.
4. History of hepatic encephalopathy.
5. History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal haemorrhage.
6. Active or history of autoimmune disease.
7. Interstitial lung disease that is symptomatic or may interfere with the detection and management of suspected drug-related pulmonary toxicity.
8. Cardiac clinical symptom or cardiovascular disease that is not well controlled.
9. Severe infection within 4 weeks prior to the start of study treatment.
10. Subjects with inadequately controlled hypertension or history of hypertensive crisis or hypertensive encephalopathy.
11. Thrombosis or thromboembolic event within 6 months prior to the start of study treatment.
12. Known genetic or acquired hemorrhage or thrombotic tendency.
13. Previous or current presence of metastasis to central nervous system.
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Death

The purpose of this study is to estimate the risk of myocardial infarction (MI)/coronary death associated with use of monotherapy low dose ASA (single antiplatelet) as well as concomitant use of monotherapy low dose ASA and proton pump inhibitors (PPIs) in first- time users of low dose ASA for secondary prevention using a UK primary care database.

Number of Anticipated Subjects: In case-control analysis 5.000-10.000

Eligibility Criteria:
Inclusion Criteria:

* As above (study population description).
* All individuals aged 50-84 years with at least two year of enrolment with the primary care physician (PCP) and a computerized prescription history of at least one year before the start of the study.

Exclusion Criteria:

* Recorded diagnosis of cancer prior to study start.
* Alcohol abuse or alcohol-related disease prior to study start.
* Patients aged ≥ 70 years with a follow-up longer than one year if having fewer than two recorded consultations with a primary care physician (PCP) during their entire follow-up (proxy for incomplete and invalid data recording) which for some individuals will be close to 8 years.
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients

The primary purpose of this study is to determine whether converting from calcineurin inhibitor (CNI) therapy to sirolimus therapy will be more effective than continuing calcineurin inhibitor therapy with respect to renal function in cardiac transplant recipients with mild to moderate renal dysfunction.


Eligibility Criteria:
Inclusion Criteria:

* Cardiac transplant recipients age 18 years or older receiving cyclosporine or tacrolimus since the time of transplant.
* 12 months after cardiac transplantation but less than 96 months post-transplantation.

Exclusion Criteria:

* Multiple-organ transplant recipients (such as heart-lung, heart-kidney, or heart after kidney transplant recipients).
* Prior or current use of sirolimus or everolimus unless administration was part of a "CNI holiday" lasting no more than 10 days.
* History of acute rejection within the last 3 months, malignancy within the last 5 years (except for adequately treated basal cell or squamous cell carcinoma of the skin), and human immunodeficiency virus (HIV) patients.
Database and Biobank of Patients With Hypersensitivity Pneumonitis

Sub-study of the main Pulmonary Fibrosis Biomarker (PFBIO) cohort (NCT02755441), recruiting patients with an MDT-diagnosis of hypersensitivity pneumonitis (HP). Patients are included for the collection of blood samples and regular clinical data.

The database and biobank will be available for studies of HP, and can be directly compared to the main PFBIO cohort, which has recruited patients with Idiopathic pulmonary Fibrosis (IPF) since 2016.

Biomarkers will be assessed as diagnostic and prognostic. Further subtyping of HP, based on blood markers (including precipitins) will also be possible with the PFBIO-HP project.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of HP at an MDT conference according to the current international guidelines
* Age of 18 years or older
* The patients must be capable of giving informed consent

Exclusion Criteria:

- Unable to sign informed consent
MRI Screening in Men at High Risk of Developing Prostate Cancer

The purpose of this study is to determine whether or not Magnetic Resonance Images (MRI) will identify high-grade cancers earlier and more frequently in men at high risk of developing prostate cancer.

In this study the study team hypothesizes MR images will identify high-grade cancers earlier and more frequently in men at high risk of developing prostate cancer. Subjects will receive gadolinium (intravenous contrast agent) as part of their research MRI exam. While the deposition of gadolinium (Gd) has been demonstrated in numerous studies, the clinical consequences of Gd deposition are unknown. Gd enhanced MRI scans provide crucial medical information regarding prostate and prostate cancer imaging and contrast-enhanced images are a component of all guidelines and the PIRADS scoring system. The study team will compare baseline prostate MR images of men at high risk of developing prostate cancer to those without an identifiable predisposition and evaluate the role of a GRS in screening men with at elevated risk of being diagnosed with prostate cancer.

Eligibility Criteria:
Inclusion Criteria:

* Male age 18 and older
* No known history of prostate cancer
* No previous prostate resection or ablation (e.g. TURP, photovaporization)

Exclusion Criteria:

* Unable to tolerate MRI due to metal fragments or claustrophobia
* Lack of a rectum
* Hip arthroplasty
Time-Restricted Feeding(TRF) on Overweight/Obese Women with Polycystic Ovarian Syndrome (PCOS)

The aims of the present study is to examine whether Time-Restricted Feeding (TRF) is a safe and effective regimen to improve insulin resistance and decrease body weight in overweight/obese Polycystic ovary syndrome (PCOS) patients over 16 weeks compared to reduced energy restriction.

Intermittent fasting regimens involve periods fasting followed by periods of eating freely. Time-Restricted Feeding (TRF) is a new form of intermittent fasting and involves shortening the eating window to 4-10 h/day. TRF is a safe lifestyle intervention for weight loss in adults with obesity. Accumulating evidence suggests that TRF is an effective means of decreasing body weight and improving insulin resistance but did not have any negative impact on eating disorder symptoms, body image perception, or eating behaviors. Polycystic ovary syndrome (PCOS) is the most common endocrine condition in productive-aged women. About 60-70 % of women with PCOS are obese or overweight, and obesity is associated with insulin resistance. Since many women with PCOS seem to have insulin resistance, compensatory hyperinsulinemia is thought to contribute to hyperandrogenism by direct stimulation of ovarian production of androgens and by inhibition of liver synthesis of SHGB. It is important to ameliorate insulin resistance in PCOS patients.The aims of the present study is to examine whether TRF is a safe and effective regimen to improve insulin resistance and decrease body weight in overweight/obese PCOS patients.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years
* BMI≥24kg/m2
* Polycystic ovary syndrome has been diagnosed

Exclusion Criteria:

* Taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic drugs or other medications as determined by the study physician;
* The body weight fluctuated more than 5% in recent 3 months.
* Liver and kidney dysfunction: renal impairment, creatinine clearance rate \< 30 mL/min/1.73 m2, transaminase increased, more than three times higher than the normal limit;
* History of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 6 months;
* History of thyroid diseases;
* Having been in pregnancy.
* Researchers believe that there are any factors that affect assessing subjects' participation in trial.
* History of malignant tumors;
* History of Cushing's syndrome, hypothyroidism, acromegaly, hypothalamic obesity;
* Currently participating in weight loss programs or weight change in the past 3 months (\> 5% current body weight)
* Patients who cannot be followed for 16 months (due to a health situation or migration)
* Patients who are unwilling or unable to give informed consent.
"The Effect of Aerobic Exercise and Strength Training on Physical Activity Level, Quality of Life and Anxiety-Stress Disorder in Young Adults With and Without Covid-19"

The purpose of this study; to examine the effects of aerobic and strength training on physical activity level, quality of life and anxiety-stress disorder in young adults with and without COVID-19. In this context, the study was planned by including 15 participants between the ages of 18-25 who had COVID-19 and 15 who did not have COVID-19. Data were collected by applying the Personal Data Form, IPAQ (International Physical Activity Form), SF-36 Quality of Life Scale, Coronavirus Anxiety Scale (CCS), Respiratory Function Tests (PFT), Six Minute Walk Test (6MWT). Aerobic training and strengthening training were applied to people with and without COVID-19 for 12 weeks. Aerobic exercise (walking) was given for 40 minutes 5 days a week, with the target heart rate being 70% of the age-corrected maximum heart rate. Strengthening exercises were applied to the upper (triceps, biceps, deltoid, pectorals) and lower (quadriceps, hamstring, gastrocnemius, tibialis anterior, hip adductors, hip flexors, hip extensors) extremities and back muscles (trapezius, latissimus dorsi) with theraband (resistance band). Significance test of the difference between two means in comparing independent group differences when parametric test assumptions are met for statistical analysis in line with the data collected from the participants; When parametric test assumptions are not met, Mann Whitney U test is used to compare independent group differences, while when parametric test assumptions are met to examine dependent group differences, the significance test of the difference between the two spouses is used; When parametric test assumptions were not met, the Wilcoxon paired two sample test was used. In all analyses, p \< .05 was considered statistically significant.


Eligibility Criteria:
Inclusion Criteria:

* Volunteering to participate in the study,
* Able to communicate, without hearing and/or visual impairment,
* Being between the ages of 18-25
* Not having a systemic disease
* Having had COVID-19 in the last 6 months to be included in the study group

Exclusion Criteria:

* Unable to communicate, hearing and/or visually impaired,
* Not being between the ages of 18-25
* Having a systemic disease other than COVID-19 infection,
* Having had COVID-19 more than 6 months ago.
Evaluation of Diagnostic Value of Molecular Markers in Renal Cancer

Renal cancer is frequent and its diagnosis mainly dependant on imaging. More than 50% of renal tumors are currently diagnosed without symptoms. However, 20% of small solid tumors are benign and this percentage is much higher in atypical cystic tumors Bosniak II and III, where 76% and 59% are benign respectively. Determining the malignancy by imaging in these cases is difficult and sometimes impossible. The fine needle aspiration (FNA) cytology or biopsy is necessary. The diagnostic sensitivity and specificity with biopsy are high, but the potential tumor contamination is a major risk. The FNA cytology is simple and safe, but its sensitivity is about 50%. We are conducting a multicentric prospective study to add the molecular markers in FNA cytology as a new diagnostic method in imaging-indeterminate renal tumors.

Four molecular markers including MN/CA9, vimentin, KIT, and S100A1 will be studied. These four markers have been reported to have a differential diagnostic value in renal tumors. MN/CA9 and vimentin are often found in conventional renal cancers. KIT is frequently expressed in renal oncocytomas and chromophobe renal cancers. S100A1 may further distinguish renal oncocytoma from chromophobe renal cancer. These markers will be analyzed by real time polymerase chain reaction (RT-PCR).

The aim of this study is to evaluate the diagnostic performance of the association cytology-molecular markers in imaging-indeterminate renal tumors (small solid tumors and cystic tumors ≥ Bosniak III). About 156 patients will be included in five French clinical centers including Saint-Etienne, Marseille, Grenoble, Toulouse, and Nancy.

The expected results will improve the preoperative diagnostic accuracy in renal tumors.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of kidney tumor \< 4 cm
* Cystic kidney tumor (Bosniak \> IIF)
* Consent signed

Exclusion Criteria:

* Benign tumor confirmed
* Impossibility to do abdominal pelvic ultra-sound or abdominal thoracic scanner
* Contraindication for renal puncture
Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations

This retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the Medication Risk Score (MRS) in a health insurance population. Our clinical tool would enable us to identify potential multi-drug interactions and potentially reduce the risk of adverse drug events (ADE) developing in these patients infected with COVID-19.

Certain investigational agents have been described in observational series or are being used anecdotally based on in vitro or extrapolated evidence. It is important to acknowledge that there are no controlled data supporting the use of any of these agents, and their efficacy for COVID-19 is unknown. FDA-approved drugs such as chloroquine/hydroxychloroquine, lopinavir/ritonavir, monoclonal IL-6 antibodies, JAK inhibitors, thalidomide, and the new investigational drug remdesivir, have been proposed for repurposing to fight COVID-19 and its complications.

A medication risk stratification strategy will be used to simulate the impacts of different potential repurposed drugs for COVID-19 and the Medication Risk Score (MRS) which is used as a predictive tool for ADEs. A retrospective study will be conducted using de-identified drug claims data for commercially insured patients.

Eligibility Criteria:
Inclusion Criteria:

* Patients enrolled with Cambia Health Solutions; Medicare/Medicaid or Commercial Health Insurance Plan
* Patients with drug claims available from 10/01/2018 to 10/31/2019

Exclusion Criteria:

* Patients with no drug claims available for 2018
* Health Plan for injectable drugs
Efficacy and Safety Study of Esomeprazole vs Omeprazole to Treat Acute Non-Variceal Upper Gastrointestinal Bleeding

The purpose of this study is to assess the efficacy and safety of Esomeprazole and Omeprazole intravenous every 12 hours for 5 days in subjects with acute non-variceal upper gastrointestinal bleeding


Eligibility Criteria:
Inclusion Criteria:

* Male or female aged 18-65 years.
* GI bleeding or with such signs within 48 hours as judged by the investigator as to have non-variceal upper GI bleeding.
* One endoscopically confirmed bleeding peptic ulcer or erosive gastritis

Exclusion Criteria:

* GI bleeding caused by Esophageal varices
* Mallory Weiss syndrome
* Zollinger-Ellison syndrome
* Suspicion of gastric malignancy at baseline endoscopy
* Post-Billroth-resection
* Unknown source of GI bleeding · 2.Unstable vital signs
Low-dose Hydrocortisone in Acutely Burned Patients

Major burns trigger the release of circulating mediators, as cytokines and endotoxin that induces a systemic inflammatory response syndrome. The cardiovascular effects are similar to those seen in septic shock. After the initial hypovolemic phase, patients with extensive burns often present a shock with increased cardiac output and reduced systemic vascular resistances. As described in septic shock, we test the hypothesis that low-dose hydrocortisone could decrease the duration of the shock period.


Eligibility Criteria:
Inclusion Criteria:

* males and females,
* between 18 and 75 year old
* who present a burned surface more than 30% of the body surface
* who need catecholamine infusion
* between J0 and J3 after the injury.

Exclusion Criteria:

* pregnancy,
* trauma,
* sepsis,
* cardiac insufficiency,
* AIDS,
* etomidate administration
Cervical Cancer Detection Using Optical Spectroscopy

The objective of the work described in this protocol is to determine the optical signatures of cervical dysplasia using optical technologies.


Eligibility Criteria:
Inclusion Criteria:

* undergoing colposcopy for the diagnosis of cervical cancer
* LEEP for the treatment of cervical cancer in early stages.
* Follow-up Pap smear in surveillance

Exclusion Criteria:

* Women under the age of 18 (minors) will be excluded from this study.
* patients will be excluded if she has had a recent episode of bleeding or preterm labor.
* Subjects who are not competent to give consent will excluded